LCAT and chronic kidney disease: Reduced HDL size may also relate to an increased fractional catabolic rate of apoAI as well as oxidative changes of apoAI occurring in CKD, as oxidized apoAI is not only a weaker activator of ABCA1 and LCAT but also has a reduced ability to switch between lipid-free and HDL-bound forms [22–24].